for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

RaQualia Pharma Inc

4579.T

Latest Trade

1,156.00JPY

Change

20.00(+1.76%)

Volume

1,842,400

Today's Range

1,112.00

 - 

1,200.00

52 Week Range

785.00

 - 

2,210.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,136.00
Open
1,125.00
Volume
1,842,400
3M AVG Volume
13.40
Today's High
1,200.00
Today's Low
1,112.00
52 Week High
2,210.00
52 Week Low
785.00
Shares Out (MIL)
20.68
Market Cap (MIL)
23,903.93
Forward P/E
109.06
Dividend (Yield %)
--

Next Event

Q3 2019 RaQualia Pharma Inc Earnings Release

Latest Developments

More

RaQualia Pharma says status of formation of JV with ZTE Coming Biotech

RaQualia Pharma updates establishment of pharmaceutical JV with ZTE Coming Biotech

RaQualia Pharma says license agreement for novel P2X7 receptor antagonist

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About RaQualia Pharma Inc

RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

Industry

Biotechnology & Drugs

Contact Info

8F, Daiwa Meieki Bldg.

1-21-19, Meieki-Minami

Nakamura-ku

+81.52.4466100

https://www.raqualia.co.jp/

Executive Leadership

Naoki Tani

President, Chief Executive Officer, Representative Director

Shinichi Koizumi

Senior Managing Executive Officer, CSO, Director

Akihiro Furuta

Managing Executive Officer, Director

Kiichiro Kawada

Managing Executive Officer

Shuzo Watanabe

Executive Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (JPY)

2017

-2.990

2018

-54.228

2019(E)

10.600
Price To Earnings (TTM)
--
Price To Sales (TTM)
28.31
Price To Book (MRQ)
6.05
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.07
LT Debt To Equity (MRQ)
0.05
Return on Investment (TTM)
-19.59
Return on Equity (TTM)
-18.79

Latest News

BRIEF-RaQualia Pharma plans pharmaceutical JV with ZTE Coming Biotech

* Says it plans to set up a JV, which will be engaged in research and development of pharmaceutical, with Shanghai-based firm ZTE Coming Biotech Co., Ltd, in May

BRIEF-RaQualia Pharma to sign license agreements with CJ HealthCare

* Says it plans to sign license agreements with CJ HealthCare regarding RQ-00000004(tegoprazan) and crystal of RQ-00000004(tegoprazan)

BRIEF-RaQualia Pharma signs license agreement with Maruho on selective Na sodium channel blocker

* Says it and Maruho Co Ltd planed to enter into license agreement, regarding selective Na sodium channel blocker, on Dec. 25

BRIEF-RaQualia Pharma ends license agreement related to EP4 antagonist

* Says it ends license agreement with Maruishi Pharmaceutical Co Ltd regarding EP4 antagonist

CORRECTED-OFFICIAL-BRIEF- RaQualia Pharma announces exercise of options

* Says 1,000 units of its 14th series options were exercised to 1 million shares of its common stock, by Daiwa Securities Co. Ltd., during period from Oct. 11 to Oct. 16

BRIEF-RaQualia Pharma says exercise of options

* Says 180 units of its 14th series options were exercised to 180,000 shares of its common stock on Oct. 12

BRIEF-RaQualia Pharma says exercise of options

* Says 100 units of its 14th series options were exercised to 100,000 shares of its stock on Oct. 11, at the price of 998.3 yen per share

BRIEF-RaQualia Pharma confirms to receive upfront payment

* Says it confirms to receive upfront payment from ASAHI KASEI PHARMA CORPORATION

BRIEF-RaQualia Pharma gets substance patent for ghrelin receptor agonist(serine derivative) in Japan

* Says it received substance patent for ghrelin receptor agonist(serine derivative) in Japan

BRIEF-RaQualia Pharma gets sodium channel blocker patent allowance in China

* Says it received an allowance for sodium channel blocker substance patent in China (Application No.201380022248.1)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up